The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease
Authors' conclusion
Empagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
Study context
- Population
- Patients with diabetes mellitus (DM) and stable coronary artery disease (CAD) started on an SGLT2i (empagliflozin); median age 73 (IQR 69, 77) years, 67% male
- Participants
- 18 patients
- Exposure
- Empagliflozin: baseline vs 1 and 3 months
- Empagliflozinn = 18
- Outcome
- cEPC levels and function (flow cytometry, immunohistochemistry, MTT assays)
- Follow-up
- Baseline, 1 month and 3 months
Methodological detailssingle-center
- Single-center
Main finding
As reported in the abstract
CD34(+)/VEGFR-2(+): baseline to 3 months, median (IQR)
0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82)
p = 0.0006
CD133(+)/VEGFR-2(+): baseline to 3 months, median (IQR)
0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95)
p = 0.0001
Cell function (CFUs): baseline to 3 months
0.25 CFUs (IQR 0, 0.5) to 2 CFUs (IQR 1, 2)
p = 0.0012
Observational data: associations, not effects.
Further findings
- No significant change in cEPC level or function after 1 month
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →